Biohaven Pharmaceutical Holding Company Ltd Investor Update Transcript
Greetings, and welcome to the Biohaven Nurtec conference call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Kim Gentile. Please go ahead.
Great. Thank you very much, and welcome to the Biohaven conference call to discuss the FDA approval of Nurtec ODT, rimegepant, orally disintegrating tablet. I'm Kim Gentile, Senior Vice President of Clinical Operations.
Speaking on today's call are Dr. Vlad Coric, our Chief Executive Officer; Dr. Elyse Stock, our Chief Medical Officer; Dr. Robert Croop, our Chief Development Officer of Neurology; and BJ Jones, our Chief Commercial Officer of Migraine and Common Diseases.
For the Q&A portion, we will be joined by Dr. Charles Conway, our Chief Scientific Officer; and Jim Engelhart, our Chief Financial Officer. Yesterday, we issued a press release announcing the FDA's approval of Nurtec ODT, an oral small molecule CGRP receptor antagonist for the acute treatment of migraine with or without or in adults. A copy of this press
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |